View Future GrowthRaphael Pharmaceutical 과거 순이익 실적과거 기준 점검 0/6Raphael Pharmaceutical의 연간 평균 수익은 5%였으며, Biotechs 산업의 수익은 연간 33.8% 증가했습니다.핵심 정보4.97%순이익 성장률16.29%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Nov 19Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company's highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including its lead product candidate for rheumatoid arthritis (RA), as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. Raphael previously announced positive proof-of-concept clinical study results for its cannabinoid-based formula for the management of RA. The study was successfully completed in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. No adverse effects were reported throughout the trial. The provisional patent application, titled, "R Raphael Pharmaceutical Inc. /Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)" (No. 63/911,729), was filed jointly with the Medical Cannabis Research and Innovation Center (MCRIC) at Rambam Health Care Campus - one of the world's leading university hospitals. Raphael and Rambam have collaborated under a sponsored research agreement signed in 2019, granting Raphael exclusive access to Rambam's world-class cannabinoid research and development program, led by Dr. Igal Louria-Hayon, who serves as both Chief Technology Officer (CTO) of Raphael and Head of the Medical Cannabis Research and innovation Center at Rambam Health Care campus. Dr. Louria-Hayon is a global expert in cannabinoid research and cell-to-cell communication. Key Findings from the Proof-of-Concept Clinical Study: Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from the hemp plant, entirely free of psychoactive cannabis components, with exceptional anti-inflammatory potential. The formulation is administered orally and demonstrated no side effects. It is designed to interact with the human endocannabinoid system by activating cannabinoid receptors expressed on immune cells. In 2025, the Company announced positive Proof-of-Concept clinical results for the use of its cannabinoid-based formula in the treatment of RA. The eight-week IRB-approved study conducted in the United States showed significant improvements in pain, sleep quality, and overall well-being, which became evident as early as week four and persisted through the end of the trial. This included a reduction in DAS28 scores from high disease activity to moderate disease severity.공시 • Jan 07Raphael Pharmaceutical Inc. Announces Positive Proof-Of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced positive proof-of-concept clinical study results for the Company's cannabinoid-based formula for the management of rheumatoid arthritis ("RA"). Citruslabs, a leading contract research organization, successfully completed this proof-of- concept clinical study in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. Key Findings of the Proof-of-Concept Clinical Study: The single-group clinical trial evaluated the effects of Raphael Pharmaceutical's highly purified cannabinoid-based formula on RA and involved 12 adult participants, each of whom used 0.5 mL of the formula daily over an eight-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial. The study's key findings: Reduction in Disease Activity Score ("DAS28"): DAS28, a comprehensive metric assessing RA disease activity, declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management. Of note, among the data: Participants in remission increased from 0% at baseline to 16.67% by Week 8. The Company intends to protect its intellectual property and highly purified cannabinoid formulation with a registered patent.공시 • Jan 01Raphael Pharmaceutical Inc. Receives Clinical Study Results After Successful Completion of a Proof-Of-Concept Clinical StudyOn December 23, 2024, Raphael Pharmaceutical Inc. (“Raphael” or the “Company”) received clinical study results after a successful completion of a proof-of-concept clinical study (the “Study”), evaluating the efficacy of the Company’s Cannabinoid based formula (“Raphael’s Formula”) in patients with active Rheumatoid Arthritis (“RA”). The single-group Study was managed by MindMate Inc./dba Citruslabs (“Citruslabs”) and conducted in Santa Monica, California, United States, under Institutional Review Board (“IRB”) approval, in compliance with the United States Food and Drug Administration (the “FDA”) regulations and in accordance with applicable industry standards and regulations. The Study evaluated the impact of Raphael’s Formula on RA related health outcomes in 12 adult participants, each of whom used 0.5 mL Raphael’s Formula product daily at home over an 8-week period, completed questionnaires and attended their local Quest Diagnostics Center for blood biomarker testing at designated intervals. According to the Study results, the questionnaires results demonstrated significant improvement in certain health parameters, including pain levels, sleep quality and overall well-being, with certain parameters remaining significantly improved through the end of the Study. The key findings from the Study results included a reduction in the Disease Activity Score (a comprehensive metric assessing RA disease activity) (“DAS28”) by 19.2%, reflecting a total decrease from high to moderate disease activity. A low DAS28 score indicates reduced disease activity and is a key goal in RA management. Additionally, the percentage of participants classified according to disease activity was evaluated and the findings included an increase in the percentage of participants classified as in remission from 0% at baseline to 16.67% at week 8, an increase in the percentage of participants classified as having low disease activity from 8.33% to 16.67% and a decreased in the percentage of participants classified as having high disease activity from 66.67% at baseline to 41.67% at week 8. The Study results also showed an improvement in health-related parameters, as evaluated through the questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8. Additionally, participant perceptions were highly positive, with approximately 83.3% of participants willing to continue using the product and approximately 91.7% of participants indicating they would recommend Raphael’s Formula to others with RA.공시 • May 27Raphael Pharmaceutical Inc. Contemplates Bankruptcy Raphael Pharmaceutical Inc. is contemplating filing for bankruptcy, as of May 25, 2023. According to company press release, the company said that additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations or seek bankruptcy protection.매출 및 비용 세부 내역Raphael Pharmaceutical가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:RAPH 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-10131 Dec 250-11130 Sep 250-11030 Jun 250-11131 Mar 250-11031 Dec 240-21130 Sep 240-11030 Jun 240-11131 Mar 240-21131 Dec 230-11130 Sep 230-31230 Jun 230-32131 Mar 230-32131 Dec 220-32130 Sep 220-32130 Jun 220-21131 Mar 220-21131 Dec 210-21130 Sep 210-11130 Jun 210-10131 Mar 210-10131 Dec 200-100양질의 수익: RAPH 은(는) 현재 수익성이 없습니다.이익 마진 증가: RAPH는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: RAPH는 수익성이 없지만 지난 5년 동안 연평균 5%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 RAPH의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: RAPH은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: RAPH의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/28 20:53종가2026/04/29 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Raphael Pharmaceutical Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Nov 19Raphael Pharmaceutical Inc. Announces Filing of Provisional Patent Application for the Treatment of Neutrophil-Dominant Autoimmune Diseases, Including Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced the filing of a provisional patent application with the United States Patent and Trademark Office. The application covers the use of the Company's highly purified cannabinoid-based technology platform in the treatment of neutrophil-dominant autoimmune diseases, including its lead product candidate for rheumatoid arthritis (RA), as well as psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus with neutrophil involvement, and gout. Raphael previously announced positive proof-of-concept clinical study results for its cannabinoid-based formula for the management of RA. The study was successfully completed in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. No adverse effects were reported throughout the trial. The provisional patent application, titled, "R Raphael Pharmaceutical Inc. /Rambam MedTech Formula for Treating Neutrophil-Dominant Autoimmune Diseases (including RA)" (No. 63/911,729), was filed jointly with the Medical Cannabis Research and Innovation Center (MCRIC) at Rambam Health Care Campus - one of the world's leading university hospitals. Raphael and Rambam have collaborated under a sponsored research agreement signed in 2019, granting Raphael exclusive access to Rambam's world-class cannabinoid research and development program, led by Dr. Igal Louria-Hayon, who serves as both Chief Technology Officer (CTO) of Raphael and Head of the Medical Cannabis Research and innovation Center at Rambam Health Care campus. Dr. Louria-Hayon is a global expert in cannabinoid research and cell-to-cell communication. Key Findings from the Proof-of-Concept Clinical Study: Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from the hemp plant, entirely free of psychoactive cannabis components, with exceptional anti-inflammatory potential. The formulation is administered orally and demonstrated no side effects. It is designed to interact with the human endocannabinoid system by activating cannabinoid receptors expressed on immune cells. In 2025, the Company announced positive Proof-of-Concept clinical results for the use of its cannabinoid-based formula in the treatment of RA. The eight-week IRB-approved study conducted in the United States showed significant improvements in pain, sleep quality, and overall well-being, which became evident as early as week four and persisted through the end of the trial. This included a reduction in DAS28 scores from high disease activity to moderate disease severity.
공시 • Jan 07Raphael Pharmaceutical Inc. Announces Positive Proof-Of-Concept Clinical Study Results for the Company's Cannabinoid-Based Formula for the Treatment of Rheumatoid ArthritisR Raphael Pharmaceutical Inc. announced positive proof-of-concept clinical study results for the Company's cannabinoid-based formula for the management of rheumatoid arthritis ("RA"). Citruslabs, a leading contract research organization, successfully completed this proof-of- concept clinical study in the United States under Institutional Review Board ("IRB") approval and in compliance with U.S. Food and Drug Administration ("FDA") regulations. Key Findings of the Proof-of-Concept Clinical Study: The single-group clinical trial evaluated the effects of Raphael Pharmaceutical's highly purified cannabinoid-based formula on RA and involved 12 adult participants, each of whom used 0.5 mL of the formula daily over an eight-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial. The study's key findings: Reduction in Disease Activity Score ("DAS28"): DAS28, a comprehensive metric assessing RA disease activity, declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management. Of note, among the data: Participants in remission increased from 0% at baseline to 16.67% by Week 8. The Company intends to protect its intellectual property and highly purified cannabinoid formulation with a registered patent.
공시 • Jan 01Raphael Pharmaceutical Inc. Receives Clinical Study Results After Successful Completion of a Proof-Of-Concept Clinical StudyOn December 23, 2024, Raphael Pharmaceutical Inc. (“Raphael” or the “Company”) received clinical study results after a successful completion of a proof-of-concept clinical study (the “Study”), evaluating the efficacy of the Company’s Cannabinoid based formula (“Raphael’s Formula”) in patients with active Rheumatoid Arthritis (“RA”). The single-group Study was managed by MindMate Inc./dba Citruslabs (“Citruslabs”) and conducted in Santa Monica, California, United States, under Institutional Review Board (“IRB”) approval, in compliance with the United States Food and Drug Administration (the “FDA”) regulations and in accordance with applicable industry standards and regulations. The Study evaluated the impact of Raphael’s Formula on RA related health outcomes in 12 adult participants, each of whom used 0.5 mL Raphael’s Formula product daily at home over an 8-week period, completed questionnaires and attended their local Quest Diagnostics Center for blood biomarker testing at designated intervals. According to the Study results, the questionnaires results demonstrated significant improvement in certain health parameters, including pain levels, sleep quality and overall well-being, with certain parameters remaining significantly improved through the end of the Study. The key findings from the Study results included a reduction in the Disease Activity Score (a comprehensive metric assessing RA disease activity) (“DAS28”) by 19.2%, reflecting a total decrease from high to moderate disease activity. A low DAS28 score indicates reduced disease activity and is a key goal in RA management. Additionally, the percentage of participants classified according to disease activity was evaluated and the findings included an increase in the percentage of participants classified as in remission from 0% at baseline to 16.67% at week 8, an increase in the percentage of participants classified as having low disease activity from 8.33% to 16.67% and a decreased in the percentage of participants classified as having high disease activity from 66.67% at baseline to 41.67% at week 8. The Study results also showed an improvement in health-related parameters, as evaluated through the questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8. Additionally, participant perceptions were highly positive, with approximately 83.3% of participants willing to continue using the product and approximately 91.7% of participants indicating they would recommend Raphael’s Formula to others with RA.
공시 • May 27Raphael Pharmaceutical Inc. Contemplates Bankruptcy Raphael Pharmaceutical Inc. is contemplating filing for bankruptcy, as of May 25, 2023. According to company press release, the company said that additional funding will be required to complete the Company’s research and development and clinical trials, to attain regulatory approvals, to begin the commercialization efforts of the Company’s product and to achieve a level of sales adequate to support the Company’s cost structure. If such sufficient financing is not received timely, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated and would then need to pursue a plan to license its assets, seek to be acquired by another entity, cease operations or seek bankruptcy protection.